Navigation Links
Rondaxe and TD2 form strategic drug development alliance

SAN FRANCISCO Feb. 18, 2010 TGen Drug Development (TD2) and Rondaxe Enterprises today announced a strategic alliance that will help emerging companies speed new high-quality treatments to cancer patients.

Rondaxe, a drug development consulting company in Syracuse, N.Y., helps emerging pharmaceutical and biotechnology companies navigate through all phases of the drug development and commercialization process. The company specializes in drug chemistry, manufacturing and controls (CMC), quality assurance and control, regulatory affairs and virtual business development.

TD2, a non-profit Scottsdale subsidiary of the Phoenix-based Translational Genomic Research Institute (TGen), specializes in guiding drug companies through the complexities of setting up and conducting clinical trials, and moving promising drug candidates through the federal review process of the U.S. Food and Drug Administration.

"We are excited to work with Rondaxe, since effective CMC management is key to the successful application and approval processes of the FDA, and moving new anti-cancer treatments to market where they can provide patient benefit," said Dr. Stephen Gately, President and Chief Science Officer at TD2.

Jeffrey M. Evans, Ph.D., co-founder and managing partner of Rondaxe, said, "Our clients will benefit measurably from the 'TD2 Solution' by receiving clear clinical and regulatory development path guidance and service support."

Today's announcement was made during InformexUSA, the world's leading fine and custom chemical industry trade show, which runs through Friday, Feb. 19, at the Moscone Convention Center in downtown San Francisco.

The TD2-Rondaxe alliance is designed to bridge a critical gap between chemistry and translational medicine. This blend of expertise will speed research discoveries through the regulatory process to bring new compounds to patients in a risk-reduced and cost-effective manner. TD2 and Rondaxe teams will focus on maximizing their clients' value proposition throughout the early stages of drug-development.

Rondaxe will provide drug development and manufacturing strategies with expertise in chemical, fermentation, drug product and analytical development, supply chain strategy, manufacturing operations, quality control, and quality assurance.

TD2 offers an integrated suite of tools that includes preclinical support, clinical trials and regulatory affairs, "The TD2 Solution."


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology news :

1. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
2. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
3. IBM and ETH Zurich form strategic partnership in nanoscience
4. Cuellars Safe and Lock Announces Strategic Alliance with Absolute Access and Security
5. Strategic farming practices could help mitigate global warming
6. Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection
7. BIO-key(R) Enters Strategic Partnership With Nlets
8. Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products
9. BIO-key(R) Enters Strategic Partnership With Nlets
10. BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant
11. Gender, coupled with diabetes, affects vascular disease development
Post Your Comments:
(Date:11/17/2015)... , November 17, 2015 Paris ... 2015.   --> Paris from 17 ... DERMALOG, the biometrics innovation leader, has invented the first ... fingerprints on the same scanning surface. Until now two different ... Now one scanner can capture both on the same ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, ... China,s pharmaceutical innovations, today announced it has ... Development Fund (KDDF) to foster collaboration between KDDF and ... and commercialization of healthcare products for the global market. ... an important source of new innovative preclinical and clinical ...
(Date:11/30/2015)... San Jose, CA (PRWEB) , ... ... ... the Content Intelligence Company, today announced tighter software integration with MarkLogic, the ... management where organizations maximize information to drive change. , Smartlogic’s Content Intelligence ...
(Date:11/27/2015)... India , November 27, 2015 /PRNewswire/ ... --> Growing popularity of companion diagnostics ... in cancer biomarkers market with pharmaceutical companies ... in-demand companion diagnostic tests. ... --> Complete report on global cancer ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology: